publication venue for
- The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices. 23:69-78. 2023
- An early cost analysis of magnetic bone growth stimulation in England. 22:139-145. 2022
- Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children. 21:1195-1201. 2021
- Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies. 15:451-463. 2015
- The economics of adalimumab for ulcerative colitis. 15:373-377. 2015
- Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. 15:13-19. 2015
- Utility values for pre-menopausal women suffering from symptomatic uterine fibroids. 15:181-189. 2015
- Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?. 14:437-450. 2014
- Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. 14:203-220. 2014
- Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor. 14:123-129. 2014
- How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. 14:81-99. 2014
- Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. 13:675-690. 2013
- Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. 13:497-511. 2013
- A review of cost–effectiveness of palivizumab for respiratory syncytial virus. 12:553-567. 2012
- Modeling cost–effectiveness of pharmaceuticals in Alzheimer's disease. 12:275-277. 2012
- Measuring and managing patient expectations for breast reconstruction: impact on quality of life and patient satisfaction. 12:149-158. 2012
- Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. 11:513-521. 2011
- The German method for setting ceiling prices for drugs: in some cases less data are required. 11:403-409. 2011
- Inventory of Cancer Guidelines: a tool to advance the guideline enterprise and improve the uptake of evidence. 11:151-161. 2011
- Health outcome and economic measurement in breast cancer surgery: challenges and opportunities. 10:583-594. 2010
- General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. 10:379-384. 2010
- QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. 10:293-308. 2010
- Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. 10:119-128. 2010
- Patient outcomes after anti TNF-α drugs for Crohn’s disease. 10:163-175. 2010
- Response to Lichtenberg. 9:505-508. 2009
- Corrigendum. 9:492-492. 2009
- How should we support pharmaceutical innovation?. 9:313-320. 2009
- Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. 9:353-364. 2009
- Optimizing the use of patient data to improve outcomes for patients: narcotics for chronic noncancer pain. 9:171-179. 2009
- Statistical analysis of cost–effectiveness data from randomized clinical trials. 6:337-346. 2006
- Ethical economics and cost–effectiveness analysis: is it ethical to ignore opportunity costs?. 5:661-665. 2005
- Quality of life of children with attention deficit hyperactivity disorder. 5:95-103. 2005
- The truly remarkable universality of half a standard deviation: confirmation through another look. 4:581-585. 2004
- Economic benefits of pioglitazone for treating patients with Type 2 diabetes. 4:135-142. 2004
- Health-related quality of life in prenatal diagnosis. 4:207-213. 2004
- Principles of good modeling practice in healthcare cost-effectiveness studies. 4:189-198. 2004
- Health economic consequences of an aging population. 2:81-83. 2002
- Health utility estimation. 2:99-108. 2002